ERBB2 and ductal breast carcinoma in situ: In contrast, the percentage of patients with ERBB2 positivity was significantly higher in the DCIS (243 [52.9%]) (P < .001), MIBC (200 [61.7%]) (P < .001), and IMPC (28 [49.1%]) (P < .001) groups.